Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 2,409 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Invasive Procedure Clear all

Conditions: Stroke, Chronic Stroke Patients, Arm Weakness as a Consequence of Stroke
Interventions: kTMP sham stimulation 9 weeks + active stimulation 9 weeks, kTMP 18 weeks; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Metastatic Breast Cancer, Breast Cancer
Interventions: Entinostat, Capecitabine; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Rochester, New York • Charlottesville, Virginia

Conditions: Bladder Cancer
Interventions: Onco4D Biodynamic Chemotherapy Selection Assay; Diagnostic Test
Lead sponsor: Animated Dynamics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Validation, Blood Pressure, Device
Interventions: Continuous non-invasive blood pressure monitoring; Device
Lead sponsor: Riverside University Health System Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Moreno Valley, California

Conditions: Chronic Spinal Cord Injury
Interventions: LIFT System; Device
Lead sponsor: ONWARD Medical, Inc.; Industry
Eligibility: 22 Years to 75 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 5
States / cities: Englewood, Colorado • Atlanta, Georgia • Cambridge, Massachusetts + 2 more

Conditions: Obsessive-Compulsive Disorder
Interventions: transcranial direct current stimulation, Sham transcranial direct current stimulation; Device
Lead sponsor: Rogers Behavioral Health; Other
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Oconomowoc, Wisconsin

Conditions: Resistant Breast Cancer, Non-metastatic Invasive Breast Cancer
Interventions: Capecitabine, Radiotherapy; Drug · Radiation
Lead sponsor: A Bapsi Chakravarthy, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: BPD - Bronchopulmonary Dysplasia
Interventions: NAVA technology to synchronize NIPPV; Device
Lead sponsor: New York Medical College; Other
Eligibility: 24 Weeks to 30 Weeks
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Valhalla, New York

Conditions: Bladder Cancer Cell Transitional, Non-Muscle Invasive Bladder Cancer, Bladder Cancer, Urinary Bladder, Transitional Cell Carcinoma of the Bladder, Urinary Bladder Neoplasms, Urologic Neoplasms, Urogenital Neoplasms, Urinary Bladder Diseases, Urologic Diseases
Interventions: TSD-001; Drug
Lead sponsor: Lipac Oncology LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 5
States / cities: Tucson, Arizona • Bakersfield, California • Los Angeles, California + 2 more

Conditions: Respiratory Distress Syndrome (Neonatal), Surfactant Deficiency Syndrome Neonatal
Interventions: Video Laryngoscopy, Direct Laryngoscopy; Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 0 Hours to 3 Days
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Schizophrenia, Psychosis
Interventions: Active Trans-cranial direct-current stimulation, Sham Trans-cranial direct current stimulation; Device
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 50 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Burns
Interventions: NICOM (non-invasive cardiac output monitor); Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions: Biospecimen Collection, Laboratory Biomarker Analysis, Patient Observation, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy; Procedure · Other · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1,195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 895
States / cities: Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 637 more

Conditions: Bladder Cancer
Interventions: bevacizumab, cisplatin, gemcitabine hydrochloride, paclitaxel, cysectomy; Biological · Drug · Procedure
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 120 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 4
States / cities: Charleston, South Carolina • Florence, South Carolina • Mt. Pleasant, South Carolina + 1 more

Conditions: Skin Laxity
Interventions: Erchonia GVS Laser; Device
Lead sponsor: Erchonia Corporation; Industry
Eligibility: 22 Years to 70 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Dunedin, Florida

Conditions: Breast Cancer, Invasive Breast Cancer, Carcinoma in Situ of the Breast
Interventions: Tissue Sample collection, Blood Sample Collection, Rectal Swab; Procedure · Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Esophageal Cancer
Interventions: Minimally invasive esophagectomy (MIE); Procedure
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 41
States / cities: Orange, California • Savannah, Georgia • Chicago, Illinois + 25 more

Conditions: Feasibility Study, Medical Device
Interventions: sphygmomanometer, Arterial Line; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 90 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder, Urethral Cancer Associated With Invasive Bladder Cancer
Interventions: trastuzumab; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Atrial Fibrillation (AF), VTE
Interventions: PAUSE Perioperative DOAC Management, ASRA Perioperative DOAC Management; Other
Lead sponsor: McMaster University; Other
Eligibility: 18 Years and older
Enrollment: 920 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: Hartford, Connecticut • Evanston, Illinois • Boston, Massachusetts + 3 more

Conditions: Arterial Thromboembolic Events, Atrial Fibrillation
Interventions: Placebo, Dalteparin; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 1,884 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Acute Phase Response
Interventions: Blood draw (venipuncture or fingerstick); Procedure
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 2 Months and older
Enrollment: 320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Breast Cancer, Breast Adenocarcinoma
Interventions: Whole breast radiation with simultaneous integrated boost (WB-SIB) to primary breast tumor, Whole breast radiation with simultaneous integrated boost (WB-SIB) to primary breast tumor and ipsilateral axillary lymph nodes; Radiation
Lead sponsor: Alexander Stessin; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Major Depressive Disorder
Interventions: Brain stimulation; Procedure
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

kTMP in Chronic Stroke

A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy

Onco4D(TM) Biodynamic Chemotherapy Selection for Bladder Cancer Patients

Is Continuous Non-Invasive Monitoring Accurate When Used on the Lower Extremity: Finger Vs Toe?

LIFT Home Study of Non-Invasive ARC Therapy for Spinal Cord Injury

Pilot Study of CBT With tDCS for Adults Being Treated for Obsessive Compulsive Disorder

Capecitabine and Radiotherapy in the Adjuvant Treatment of Resistant Breast Cancer

Randomized Control Trial: Synchronized Non-invasive Positive Pressure Ventilation Versus Non Synchronized Non Invasive Positive Pressure Ventilation in Extremely Low Birth Weight Infants

Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer

Video vs. Direct Laryngoscopy for Less Invasive Surfactant Administration

Non-Invasive Direct Current Stimulation for Cognition in Schizophrenia

Cardiac Output Monitoring in Burn Patients

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery

An Evaluation of the Erchonia Laser As a Non-Invasive Treatment to Improve the Appearance of Skin Laxity

Prospective Breast Cancer Biospecimen Collection

Esophagectomy in Treating Patients With High-Grade Dysplasia of the Esophagus or Stage I, Stage II, or Stage III Esophageal Cancer

Clinical Feasibility of a Conformal Ultrasound Blood Pressure Sensor

Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium

Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure

Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)

Disorders of the Acute Phase Response Following Trauma and Invasive Surgery

Definitive Radiation Therapy for Inoperable Breast Cancer

Invasive Decoding and Stimulation of Altered Reward Computations in Depression Patients